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increased risk of thromboembolism and bleeding events compare to
antiplatelets.
Objective: To study the safety and effectiveness of the DAWN AC
computer-assisted oral anticoagulant dosage program compare to
manual adjustment by doctors.
Method: In this retrospective study, we compared the use of
physician dosing (year 2015) versus computer dosing (year 2017) in
the management of patients in the warfarin clinic of the National
Heart Institute, Malaysia. Our outcome measures are time in
therapeutic range, thromboembolic events and major bleedings.
Results: A total number of 187 patients were recruited: 85
patients from manual dosing group in 2015 and 103 patients in
computer assisted group in 2017. Most common indications for
warfarin are atrial fibrillation, mechanical mitral valve replacement
and mechanical aortic valve replacement. Mean CHA2DS2-VASc
score were 2.54 ±1.16 and 2.15±1.16 in manual group and in
computer assisted group respectively (p 0.11). Mean HASBLED score
were 1.16 ±0.962 in manual vs 1.16 ±1.03 in computer dosing
(p 0.95). Time in therapeutic range was not statistically significant
different between two groups, with mean TTR of 78.7% in manual
dosage vs 69.9% in computer assisted group (p 0.17). Time in
therapeutic range of INR above 70% is 56.5 % of patients in manual
group , as compared to 54.4% in computer assisted group (p 0.88).
There was no new stroke in both groups during one year follow-up.
There were 2.9% of major bleeding in computer assisted group, as
compared to 1.1% bleeding in manual monitoring group (p 0.63).
Conclusion: Computer assisted dosing system is as effective as
manual dosing in term of TTR in patients taking warfarin. There was
no statistically significant different in event rates in both groups.
There is numerically higher in bleeding in computer assisted group
but it was not statistically significant. Computer assisted program
can be safely implemented in the hospital and community clinics
without direct supervision under physicians.
doi:10.1016/j.ijcard.2019.11.035
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Background: Clopidogrel high on-treatment platelet reactivity
(HPR) is an independent predictor of major adverse cardiovascular
events(MACE) in myocardial infarction(MI) patients with drug eluting
stents(DES). Despite published guidelines in which more potent
ticagrelor, is preferred, clopidogrel remains the treatment choice in
Malaysia due to cost reason. The use of point-of-care(POC) instruments
in phenotype-guided escalated therapy (GES) could be explored.
Objective: To determine the 1-year clinical and economic outcomes
of GES in patients post MI with DES.
Materials and Methods: Patients admitted between Sep-Dec 2017
with MI and DES, had POC platelet function testing(PFT)(Multiplate®)
andCYP2C19 genotyping(SpartanRxAssay) performedupon discharge.
Patients with clopidogrel HPR were switched to ticagrelor. One year
follow-up and budget impact analysis were assessed.
Results: Out of the 40 patients recruited, mean age was 56.08±
11.33 years and 92.5% were male. Approximately one third had
wildtype(WT) CYP2C19 *1/*1 genotype, while the remaining had ≥1
loss-of-functional alleles(LOF) [(WT: 30.0%; 1 LOF: 62.5%; 2 LOF:
7.5%); (Percentage of clopidogrel HPR: 0% vs. 8% vs. 33.3% )]. None
had *17 gain-of-function alleles. Clopidogrel reactivity(MEA ADP)
was significantly higher in patients with more LOF compared to
WT [median(IQR): WT vs. 1LOF vs. 2LOF: 246(268), 316(189.50) and
478(-) respectively, p=0.06]. Aspirin HPR (MEA ASPI ≥300 AU*min)
made up 10.0% of the population. All three with clopidogrel HPR
(MEA ADP≥600AU*min), 10.7% of those who had ≥1 LOF, were
switched to ticagrelor. All patients had normal on-treatment platelet
reactivity and were alive at discharge. At 1-year, MACE were 12.5%.
Significant associations were neither observed between presence of
LOF and MACE (p = 0.627), nor between those who initially had
clopidogrel HPR and MACE (p=1.000). At 1-year, the cost of GES
(including drugs, PFT and MACE) of 40 patients was lower compared
to standard therapy(SDT) and guideline-recommended ticagrelor-
for-all therapy(drugs and MACE) (RM 90,331.60 vs. RM 117,688 vs.
RM 184,936).
Conclusions: Presence of LOF is significantly associated with
clopidogrel HPR but only 10.7% were switched to ticagrelor due to
HPR. CYP2C19 genotyping could not be used as a sole guidance in
antiplatelet therapy. GES is more cost effective and had lower 1-year
MACE compared to standard therapy.
doi:10.1016/j.ijcard.2019.11.036
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Background: Randomised phase III studies had proven the
efficacy and safety profile of direct oral anticoagulant (DOAC) over
warfarin in stroke and systemic embolism prevention for patients
with atrial fibrillation (AF) and venous thromboembolism (VTE).
Nevertheless, patients’ quality of life (QOL) and treatment satisfaction
was not explored in these studies.
Objective: The primary objective of this study was to compare
the QOL and treatment satisfaction of patients on long term warfarin
versus DOACs in a tertiary hospital in Malaysia.
Methods: This is a cross-sectional study of patients with non-
valvular AF (NVAF) or VTE on long term warfarin versus DOACs
attending the cardiology clinic and anticoagulation clinic of
University Malaya Medical Centre from 1 st July 2016 to 30 st June
2018. Patients’ QOL was assessed by using Short Form 12v2 Health
Survey (SF12v2); while treatment satisfaction was assessed by using
Perception of Anticoagulation Treatment Questionnaire 2 (PACT-Q2).
Results: Of 208 patients, 52.4% received warfarin and remaining
47.6% received DOACs. The warfarin group was significantly younger
and had longer treatment duration (p b 0.001); while DOAC group
had significant more underlying NVAF (p b 0.001) and polypharmacy
(p= 0.003).
There was no significant difference in the score of physical
component summary (PCS) (p = 0.083), mental component summary
(MCS) (p = 0.665) and each domain of SF-12v12 (p = 0.058 – 0.953)
between anticoagulant groups. There were no differences between the
2 groups of anticoagulants even after adjustment of age. The satisfaction
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score was significant higher in DOACs group compared to warfarin
group (p = 0.003); but there was no difference in the convenience
score (p = 0.234).
Hospitalisation rate was significantly higher (p = 0.002) in
warfarin group. Only 45.0% of patients achieved good time in
therapeutic range (TTR).
Conclusions: Despite no significant difference in QOL, patients
with AF or VTE who were treated with DOACs demonstrated better
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Background: Antiplatelet agents remain the mainstay of therapy
in acute coronary syndrome (ACS). There is limited information on
outcomes of prior antiplatelet (PAP) use in ACS patients.
Objective: To evaluate the impact of PAP use in patients
presenting with ACS.
Materials & Methods: This retrospective observational cohort
study includedACS patientswhoadmitted toHospital Serdang between
January to December 2016. These patients were recruited through
consecutive sampling. The rates of cardiovascular events (a composite
of death, ACS, stroke or stent thrombosis) were assessed during
hospitalisation and up to one year after discharge. PAP is defined as
patients who use antiplatelet agents within 30 days before admission
for ACS treatment. Logistic regression was used to compare
cardiovascular events during hospitalization and after discharged.
Results: 457 patients were included [77.5% male, mean age
57.0 (1.6) years]. Among of them, 33.9% (n=155) had PAP. PAP
users were associated with lower cardiovascular events during
hospitalization compared with non-PAP users(2.6% vs 6.6%; adjusted
OR 0.32, 0.10-0.99; p=0.048). Cardiovascular events after hospital
discharge were similar in both groups (30.1% in PAP vs 20.9% in non-
PAP; adjusted OR 1.55, 0.95-2.54, p=0.080).
Conclusions: Our study shows prior use of antiplatelet therapy was
associatedwith lower risk of cardiovascular event duringhospitalization.
Further study will be beneficial to explore further the findings.
doi:10.1016/j.ijcard.2019.11.038
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Background: Prognostic and risk assessment of acute coronary
syndrome is a crucial role in weighing the necessity of invasive
revascularization procedures. Reduced left ventricular ejection
fraction (LVEF), multi vessel disease, more severe and proximal
coronary lesions, older age, significant depression and more severe
angina are predictors of poor outcome.
Objective: To identify the outcomes of patients with impaired and
normal left ventricular function (with documented echocardiography)
who underwent for per cutaneous coronary intervention for significant
coronary artery disease.
Materials & Methods: Retrospective analysis of National
cardiovascular disease-Percutaneous Coronary Intervention (NCVD-PCI)
registry database from year of 2007 to 2014.
Results: Out of total 18582 patients, documented echocardiography
noted in 7248 patients. 1207 (16.7%) patients were diagnosed with
impaired LV function (ejection fraction b40%) while 4366 (60.2%)
patients had good LV function (ejection fraction N50%). The rest
1675 (23.1%) with LV function of 40-50% are excluded in this analysis.
Similar mean age for both study groups (57.45 ± 10.38 years) with
predominantly male patients. 23.9% patients with poor LV function and
22.2%patients with good LV function are active smokers. Diabetes was
more commonly associated in impaired left ventricular patients (50.9%
vs 44.0%). Hypertension and dyslipidemia were more commonly seen
in patients with good LV function. Previous history of percutaneous
coronary intervention in 598 (13.7%) patients from good LV function
group and 173 (14.3%) individuals with impaired LV function. 579
(48.0%) impaired cardiac function patients presented with acute
coronary syndrome whereas 1680 (38.5%) patients with normal LV
function presented as it is. Immediate hospital outcome such as overall
death rates (all- cause mortality) are more common in impaired LV
function group 1.1% vs 0.4% in comparison to the group of patients with
good LV function. Impaired left ventricular ejection fraction b40%
patients have significantly worse survival (HR: 2.54, 95% CI, 1.25-5.14;
Pb 0.05) than patients with preserved left ventricular function on long
term follow up.
Conclusions: Coronary artery disease patients with documented
poor left ventricular ejection fraction are carrying significant poor
clinical outcomes in terms of both immediate and long term
outcomes even with percutaneous coronary interventions.
doi:10.1016/j.ijcard.2019.11.039
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Background: Prognostic and risk assessment of acute coronary
syndrome is a crucial role in weighing the necessity of invasive
revascularization procedures. Reduced left ventricular ejection
fraction (LVEF), multi vessel disease, more severe and proximal
coronary lesions, older age, significant depression and more severe
angina are predictors of poor outcome.
Objective: To identify the outcomes of patients with impaired and
normal left ventricular function (with documented echocardiography)
who underwent for per cutaneous coronary intervention for significant
coronary artery disease.
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